HC Wainwright Has Optimistic Outlook of PDSB FY2026 Earnings

PDS Biotechnology Corporation (NASDAQ:PDSB) – Equities research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for PDS Biotechnology in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst J. Pantginis now anticipates that the company will earn ($0.71) per share for the year, up from their prior forecast of ($0.73). The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PDS Biotechnology’s FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.63) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, PDS Biotechnology has an average rating of “Hold” and a consensus price target of $9.00.

PDS Biotechnology Trading Up 0.2%

Shares of NASDAQ PDSB opened at $0.61 on Thursday. PDS Biotechnology has a one year low of $0.51 and a one year high of $1.92. The firm has a market capitalization of $31.75 million, a PE ratio of -0.81 and a beta of 1.20. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 1.26. The business has a 50-day moving average price of $0.70 and a two-hundred day moving average price of $0.85.

PDS Biotechnology (NASDAQ:PDSB) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.06.

Institutional Trading of PDS Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC purchased a new position in PDS Biotechnology in the fourth quarter valued at about $2,182,000. Inspirion Wealth Advisors LLC lifted its holdings in shares of PDS Biotechnology by 338.5% during the 3rd quarter. Inspirion Wealth Advisors LLC now owns 344,394 shares of the company’s stock valued at $348,000 after buying an additional 265,862 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of PDS Biotechnology by 116.1% during the 3rd quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after buying an additional 156,662 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of PDS Biotechnology by 117.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock valued at $151,000 after buying an additional 106,300 shares in the last quarter. Finally, Susquehanna International Group LLP increased its holdings in PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares during the last quarter. 26.84% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.